SCHEMBL21761825

SCHEMBL21761825

O=C(NCCCNCCCN(CCCNC(=O)C(F)(F)F)C(=O)C(F)(F)F)C(F)(F)F

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA3 P07451 2/20 0.68
CA5A P35218 2/20 0.68
CA5B Q9Y2D0 2/20 0.68
CA14 Q9ULX7 2/20 0.68
CA12 O43570 1/20 0.68
CA2 P00918 1/20 0.68
CA4 P22748 1/20 0.68
CA6 P23280 1/20 0.68
CA7 P43166 1/20 0.68
CA9 Q16790 1/20 0.68
SMN1; SMN2 Q16637 3/20 0.55
ALDH1A1 P00352 2/20 0.55
POLB P06746 1/20 0.55
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
EPHX1 P07099 1/20 0.46
GLA P06280 1/20 0.38
HPGD P15428 1/20 0.38
ALOX12 P18054 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21762356 0.97 CA3 (0.69) CA3CA5ACA5BCA14CA12
SCHEMBL24703389 0.92 CA3 (0.66) CA3CA5ACA5BCA14CA12
SCHEMBL3138315 0.91 CA14 (0.62) CA3CA5ACA5BCA14CA12
SCHEMBL22522057 0.88 CA3 (0.53) CA3CA5ACA5BCA14CA12
SCHEMBL22688574 0.85 CA14 (0.56) CA3CA5ACA5BCA14CA12
Trifluoroacetic Acid SCHEMBL7533514 0.85 CA14 (0.53) CA3CA5ACA5BCA14CA12
SCHEMBL22606453 0.84 CA3 (0.53) CA3CA5ACA5BCA14CA12
SCHEMBL3142216 0.84 CA3 (0.95) CA3CA5ACA5BCA14CA12
SCHEMBL10228415 0.82 CA3 (1.00) CA3CA5ACA5BCA14CA12
SCHEMBL12936102 0.82 CA3 (1.00) CA3CA5ACA5BCA14CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230355775-A1 NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF Suzhou Ribo Life Science Co., Ltd. (CN) 2023-11-09 US disclosed
US-20230257827-A1 CONJUGATES AND PREPARATION AND USE THEREOF Suzhou Ribo Life Science Co., Ltd. (CN) 2023-08-17 US disclosed
US-11660347-B2 Nucleic acid, composition and conjugate containing same, preparation method, and use thereof Suzhou Ribo Life Science Co., Ltd. (CN) 2023-05-30 US disclosed
US-20230132756-A1 DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREOF AND USE THEREOF Suzhou Ribo Life Science Co., Ltd. (CN) 2023-05-04 US disclosed
US-20220395526-A1 NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE Suzhou Ribo Life Science Co., Ltd. (CN) 2022-12-15 US disclosed
US-20220389428-A1 NUCLEIC ACID, COMPOSITION AND CONJUGATE COMPRISING THE SAME, AND PREPARATION METHOD AND USE THEREOF Suzhou Ribo Life Science Co., Ltd. (CN) 2022-12-08 US disclosed
US-11492620-B2 Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof Suzhou Ribo Life Science Co., Ltd. (CN) 2022-11-08 US disclosed
US-20220049249-A1 DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREOF AND USE THEREOF Suzhou Ribo Life Science Co., Ltd. (CN) 2022-02-17 US disclosed
US-20210401994-A1 SIRNA CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF Suzhou Ribo Life Science Co., Ltd. (CN) 2021-12-30 US disclosed
US-20210275564-A1 NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, AND USE THEREOF Suzhou Ribo Life Science Co., Ltd. (CN) 2021-09-09 US disclosed
EP-3862024-A1 SIRNA CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF Suzhou Ribo Life Science Co., Ltd. (CN) 2021-08-11 EP disclosed
EP-3842534-A1 NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, AND USE THEREOF Suzhou Ribo Life Science Co., Ltd. (CN) 2021-06-30 EP disclosed
US-20210032623-A1 NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF Suzhou Ribo Life Science Co., Ltd. (CN) 2021-02-04 US disclosed
US-20200360522-A1 NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF Suzhou Ribo Life Science Co., Ltd. (CN) 2020-11-19 US disclosed
US-20200338201-A1 CONJUGATES AND PREPARATION AND USE THEREOF SUZHOU RIBO LIFE SCIENCE CO. LTD. (CN) 2020-10-29 US disclosed
EP-3719127-A1 NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE Suzhou Ribo Life Science Co., Ltd. (CN) 2020-10-07 EP disclosed
EP-3718572-A1 NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD AND USE Suzhou Ribo Life Science Co., Ltd. (CN) 2020-10-07 EP disclosed
EP-3719125-A1 NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE Suzhou Ribo Life Science Co., Ltd. (CN) 2020-10-07 EP disclosed
EP-3719126-A1 NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF Suzhou Ribo Life Science Co., Ltd. (CN) 2020-10-07 EP disclosed
WO-2020038377-A1 NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, AND USE THEREOF 苏州瑞博生物技术有限公司 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220049249-A1 DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREOF AND USE THEREOF POLN, POLM, DUT CA3 1689/4885CA5A 861/4885CA5B 1079/4885
US-11492620-B2 Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof POLN, POLM, DUT CA3 1689/4885CA5A 861/4885CA5B 1079/4885
US-20220395526-A1 NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE NSUN2, RNGTT, ADAR CA3 4225/4885CA5A 3720/4885CA5B 3765/4885
US-20220389428-A1 NUCLEIC ACID, COMPOSITION AND CONJUGATE COMPRISING THE SAME, AND PREPARATION METHOD AND USE THEREOF NSUN2, RNGTT, ADAR CA3 4396/4885CA5A 3954/4885CA5B 3845/4885
US-11660347-B2 Nucleic acid, composition and conjugate containing same, preparation method, and use thereof APOB, C1QBP, APOL1 CA3 3728/4885CA5A 4255/4885CA5B 4247/4885
US-20230355775-A1 NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF APOB, C1QBP, APOL1 CA3 3728/4885CA5A 4255/4885CA5B 4247/4885
US-20230132756-A1 DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREOF AND USE THEREOF POLN, POLM, DUT CA3 1689/4885CA5A 861/4885CA5B 1079/4885
US-20210032623-A1 NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF TEK, IGF2BP1, METTL16 CA3 4718/4885CA5A 4422/4885CA5B 4627/4885
US-20200360522-A1 NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF APOB, C1QBP, APOL1 CA3 3728/4885CA5A 4255/4885CA5B 4247/4885
US-20210401994-A1 SIRNA CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF VARS1, IGSF11, MCTS1 CA3 4778/4885CA5A 4150/4885CA5B 4488/4885
US-20200338201-A1 CONJUGATES AND PREPARATION AND USE THEREOF SLC10A1, GOT1, SLC19A1 CA3 3347/4885CA5A 642/4885CA5B 912/4885
US-20210275564-A1 NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, AND USE THEREOF NSUN2, SLC10A1, BCDIN3D CA3 4195/4885CA5A 3530/4885CA5B 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.